OSTPDL1: A phase II study of avelumab, a monoclonal antibody targeting programmed death-ligand 1 (PD-L1) in adolescent and young adult patients with recurrent or progressive osteosarcoma Meeting Abstract
| Authors: | Bishop, M. W.; Kaste, S. C.; Sykes, A.; Pan, H.; Dela Cruz, F. S.; Whittle, S.; Mascarenhas, L.; Thomas, P. G.; Youngblood, B.; Harman, J. L.; Wang, L. L.; Meyers, P. A.; Pappo, A. S. |
| Abstract Title: | OSTPDL1: A phase II study of avelumab, a monoclonal antibody targeting programmed death-ligand 1 (PD-L1) in adolescent and young adult patients with recurrent or progressive osteosarcoma |
| Meeting Title: | 56th Annual Meeting of the American Society of Clinical Oncology (ASCO) |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 38 |
| Issue: | 15 Suppl. |
| Meeting Dates: | 2020 May 29-31 |
| Meeting Location: | Virtual |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2020-05-20 |
| Start Page: | 529s |
| Language: | English |
| ACCESSION: | WOS:000560368300240 |
| PROVIDER: | wos |
| DOI: | 10.1200/JCO.2020.38.15_suppl.10521 |
| Notes: | Meeting Abstract: 10521 -- Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work